Antithrombin Market: Current Analysis and Forecast (2021-2027)

Rapportbeskrivning

BEGÄR GRATIS EXEMPEL PDF

Antitrombinmarknaden förväntas uppleva en CAGR på cirka 5% under prognosperioden (2021–2027). Antithrombin is a small glycoprotein produced by the liver that inactivates many enzymes of the coagulation system by neutralizing the enzymatic activity of thrombin. Antithrombin deficiency can lead to thromboembolism, a condition in which a clot develops in a blood vessel, this can severely affect the functioning of other organs like the kidneys, brain, gastrointestinal tract, and lungs. Moreover, this can create complications during & after surgeries, and during pregnancy, untreated antithrombin deficiency is associated with up to a 50% risk of venous thromboembolism (VTE) and a relative risk of pregnancy loss of 2.1 with a 5-fold increase in stillbirths. Furthermore, according to the Centers for Disease Control and Prevention (CDC), in 2020, a total of 3,613,647 births were registered in the U.S.

Some of the major companies operating in the antithrombin market include F Grifols S.A., Octapharma AG, LFB USA Inc., CSL Limited, Takeda Pharmaceuticals, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, Lee Biosolutions Inc., BDI Pharma Inc.

Insikter som presenteras i rapporten

“Amongst Application, the therapeutic category accounted for the majority share in the market in 2020”

Based on application, the antithrombin market is segmented into therapeutic, research, and diagnostics. the therapeutic category is anticipated to witness a considerable growth rate during the forecast period. This is mainly due to the increasing prevalence of blood clotting diseases and increases in the therapeutic and diagnostic usage of Antithrombin. Additionally, the rising cases of cardiac disorders such as heart failure, high blood pressure, and coronary artery diseases due to blood clotting, are also contributing to the growth of the market. For instance, as per the data published by the American Society of Hematology 900,000 people in the United States develop blood clots yearly, and they are accountable for approximately 100,000 casualties each year.  

BEGÄRAN OM ANPASSNING

“Amongst Source, the goat milk category is expected to witness the highest CAGR during the forecast period”

Based on source, the antithrombin market is segmented into human, goat milk, and others. The goat milk category is anticipated to witness a significant growth rate during the forecast period. Owing to its high capacity of producing antithrombin protein, the F.D.A. also approved the goats used to make the drug, the first such animals cleared under guidelines the agency to regulate the use of transgenic animals in the nation’s drug and food supply. Additionally, antithrombin III deficiency is a blood-clotting disease that main reason for Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). For instance, according to the NCBI, the incidence of pulmonary embolism (PE) ranges from 39 to 115 per 100 000 population annually; for DVT, the incidence ranges from 53 to 162 per 100,000 people.

“Amongst Dosage form, the lyophilized category is expected to witness a considerable growth rate during the forecast period”

Based on dosage form, the antithrombin market is categorized into lyophilized and liquid. The lyophilized category captured a significant share of the market and is anticipated to witness a considerable growth rate during the forecast period. This is mainly due to its wide application in the treatment of thrombin deficiency and coronary heart diseases (CAD). Moreover, lyophilized antithrombin is also used to treat venous thromboembolism (VTE) and peripheral artery diseases (PAD) which is an underdiagnosed and serious, yet preventable medical condition that can cause disability and death.

"Nordamerika kommer att bevittna betydande tillväxt under prognosperioden"

For a better understanding of the market, the report provides a detailed analysis of major regions and countries including North America (U.S., Canada, Rest of North America); Europe (Germany, U.K., France, Spain, Italy, Rest of Europe); Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific) and Rest of World. North America accounted for a significant market share during the forecast period. This is mainly due to the prevalence of antithrombin deficiency diseases such as Peripheral Artery Disease (PAD), heart-related diseases obesity, AT deficiency, etc. Moreover, the presence of major pharmaceutical & drug manufacturing companies and well-settled healthcare infrastructure are also contributing to the growth of this market. for instance, according to the data published by the U.S. Department of Health & Human Services in 2018, antithrombin deficiency is expected to occur in about 1 in 2,000 people across the globe.

TALA MED ANALYTIKER

Anledningar till att köpa denna rapport:

• Studien inkluderar marknadsdimensionering och prognosanalys validerad av autentiserade nyckelexperter inom branschen.
• Rapporten presenterar en snabb genomgång av branschens övergripande prestanda med en blick.
• Rapporten täcker en djupgående analys av framstående branschkollegor med primärt fokus på nyckelekonomi, produktportfölj, expansionsstrategier och den senaste utvecklingen.
• Detaljerad undersökning av förare, begränsningar, nyckeltrender och möjligheter som råder i branschen.
• Studien täcker heltäckande marknaden över olika segment.
• Djupdykning regional nivå analys av branschen.

Anpassningsalternativ:

The antithrombin market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

Du kan också köpa delar av denna rapport. Vill du kolla in ett avsnitt klokt
prislista?

Ta kontakt med teamet

Forskningsmetodik

Research Methodology for the Antithrombin market Analysis (2021-2027)

Analyzing the historical market, estimating the current market, and forecasting the future market of the antithrombin market were the three major steps undertaken to create and analyze the adoption of the antithrombin market in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the antithrombin market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:

Sök mer information om forskningsmetodik

Analys av historisk marknadsstorlek

Steg 1: Fördjupad studie av sekundära källor:

Detail secondary study was conducted to obtain the historical market size of the antithrombin market through company internal sources such as årsredovisningar och bokslut, resultatpresentationer, pressmeddelanden, etc., och externa källor inklusive tidskrifter, nyheter och artiklar, statliga publikationer, konkurrentpublikationer, sektorsrapporter, tredjepartsdatabas och andra trovärdiga publikationer.

Steg 2: Marknadssegmentering:

After obtaining the historical market size of the antithrombin market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as application, source, and dosage form. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.

Steg 3: Faktoranalys:

Efter att ha förvärvat den historiska marknadsstorleken för olika segment och delsegment genomförde vi en detaljerad faktoranalys to estimate the current market size of the antithrombin market. Further, we conducted factor analysis using dependent and independent variables such as various application, source, and dosage form of the antithrombin market. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, and business expansion, in the antithrombin market sector across the globe.

BEGÄRAN OM ANPASSNING

Aktuell marknadsstorleksuppskattning och prognos

Aktuell marknadsstorlek: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the antithrombin market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.

Uppskattning och prognoser: För marknadsuppskattning och prognos tilldelades vikter till olika faktorer inklusive drivkrafter och trender, begränsningar och tillgängliga möjligheter för intressenterna. Efter att ha analyserat dessa faktorer användes relevanta prognostekniker, dvs. top-down/bottom-up-metoden för att komma fram till marknadsprognosen för 2027 för olika segment och delsegment på de stora marknaderna globalt. Den forskningsmetod som används för att uppskatta marknadsstorleken omfattar:

• The industry’s market size, in terms of revenue (USD) and the adoption rate of the antithrombin market across the major markets domestically
• Alla procentandelar, uppdelningar och uppdelningar av marknadssegment och undersegment
• Key players in the antithrombin market in terms of solutions offered. Also, the growth strategies adopted by these players to compete in the fast-growing market

Validering av marknadsstorlek och andel

Primärforskning: Djupintervjuer genomfördes med Key Opinion Leaders (KOL) inklusive toppchefer (CXO/VP:er, försäljningschef, marknadschef, operativ chef, regionchef, landschef, etc.) över större regioner. Primära forskningsresultat sammanfattades sedan och statistisk analys utfördes för att bevisa den angivna hypotesen. Insatser från primärforskning konsoliderades med sekundära resultat, vilket förvandlade information till praktiska insikter.

Uppdelning av primära deltagare i olika regioner

TALA MED ANALYTIKER

Marknadsteknik

The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the antithrombin market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of application, source, and dosage form in the antithrombin market.

The main objective of the antithrombin market Study

The current & future market trends of the antithrombin market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:

• Analyze the current and forecast market size of the antithrombin market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
• Segments in the study include areas of application, source, and dosage form.
• Define and analysis of the regulatory framework for the antithrombin market industry.
• Analysera värdekedjan involverad med närvaron av olika mellanhänder, tillsammans med analysera kundernas och konkurrenternas beteenden i branschen.
• Analyze the current and forecast market size of the antithrombin market for the major region.
• Viktiga regioner och länder som studeras i rapporten inkluderar Nordamerika (USA, Kanada, Övriga Nordamerika); Europa (Tyskland, Storbritannien, Frankrike, Spanien, Italien, Övriga Europa); Asien-Stillahavsområdet (Kina, Indien, Japan, Australien, Sydkorea, Övriga Asien-Stillahavsområdet) och Övriga världen.
• Company profiles of the antithrombin market and the growth strategies adopted by the market players to sustain in the fast-growing market
• Djupdykning regional nivå analys av branschen

Du kan också köpa delar av denna rapport. Vill du kolla in ett avsnitt klokt
prislista?

Ta kontakt med teamet